Loading
The standard 1-to-5 scale doctors use to grade every side effect in a trial: 1 mild, 2 moderate, 3 severe or needing hospital care, 4 life-threatening, 5 death. 'Grade 3-4 events in 40% of patients' is the usual headline safety figure.
The NCI Common Terminology Criteria for Adverse Events (now v5.0) defines each toxicity by grade (neutropenia by neutrophil count, diarrhoea by stool frequency, neuropathy by function), allowing comparison across trials. Reports distinguish all-cause adverse events, treatment-related (attributed by the investigator), serious (hospitalisation or worse) and treatment-emergent, and often quote grade ≥3 rates and discontinuations. Limitations: grading is done by clinicians, who under-report symptoms compared with patient-reported PRO-CTCAE; chronic low-grade toxicity of long-term pills is poorly captured by grade alone; and different drugs' grade 3 events are not equally burdensome (asymptomatic lab abnormalities versus disabling neuropathy).
Shares Dose-limiting toxicity (DLT), Dose reduction, interruption and discontinuation.
Shares Dose-limiting toxicity (DLT), Dose reduction, interruption and discontinuation.
Shares Dose reduction, interruption and discontinuation, Immune-related adverse events (irAEs).
Shares Dose reduction, interruption and discontinuation, Immune-related adverse events (irAEs).
Shares Dose-limiting toxicity (DLT), Dose reduction, interruption and discontinuation, Quality of life and patient-reported outcomes (QoL, PRO).
Shares Dose reduction, interruption and discontinuation, Immune-related adverse events (irAEs).
Shares Dose-limiting toxicity (DLT), Dose reduction, interruption and discontinuation.